Shared on 17 Aug 25

Fair value Decreased 5.23%

The slight decrease in consensus revenue growth expectations and a lower future P/E multiple have led analysts to reduce their fair value estimate for Pacira BioSciences from $30.60 to $29.00. What's in the News Pacira completed a $50.04 million buyback, repurchasing 1,955,589 shares (4.23%) under its May 2025 authorization and previously completed a $25 million buyback (837,240 shares, 1.8%) under its May 2024 authorization.

Read more

0 votesShare

Shared on 01 May 25

Fair value Decreased 14%

Read more

0 votesShare

Shared on 23 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

0 votesShare

Shared on 17 Apr 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

0 votesShare

Shared on 09 Apr 25

Fair value Increased 12%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

0 votesShare

Shared on 02 Apr 25

Fair value Increased 3.93%

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

0 votesShare

Shared on 26 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

0 votesShare

Shared on 19 Mar 25

AnalystConsensusTarget made no meaningful changes to valuation assumptions.

Read more

0 votesShare

Shared on 11 Mar 25

Fair value Increased 0.43%

AnalystConsensusTarget has increased revenue growth from 6.5% to 10.1%, increased profit margin from 9.8% to 15.3% and increased future PE multiple from 7.5x to 11.6x.

Read more

0 votesShare